IPR2015-00291 decided a petition filed by Daiichi Sankyo Co. Ltd. against USPN 8,168,181 owned by Alethia Biotherapeutics, Inc. The ‘181 patent issued from a continuation-in-part of the U.S. national phase of a PCT application and contains claims drawn to methods of impairing osteoclast differentiation, useful in treating various bone diseases. The Board denied the Patent … Continue Reading
The material contained on this blog is provided for informational purposes only and does not constitute legal advice. Views expressed are those of the author and are not to be attributed to Marshall, Gerstein & Borun LLP or any of its clients. The publication and receipt of any information contained on this blog does not create an attorney-client relationship with Marshall, Gerstein & Borun LLP or with any of its attorneys. Readers should not act upon any information on this site without seeking professional legal counsel.